DNA

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour  ...

SpyGlass Pharma Presents 18-Month Data Demonstrating Compelling Visual Acuity Results with Their IOL-mounted Innovative Drug Delivery Platform

All patients achieved 20/30 or better best corrected distance visual acuity (BCDVA)Significant IOP reduction at 18 months was also demonstrated...

Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore

The STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study is a multi-institutional study led by STCC with the goal of...

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

Company to highlight preclinical study of ARV-393, an investigational PROTAC BCL6 degrader, in combination with standard of care therapiesNEW HAVEN,...

Next Mission to Space Station Features Nanomaterials to Treat Osteoarthritis, New Materials for Lifelike Robotics, a Holographic Microscope, and More

SpaceX's 32nd resupply mission for NASA includes ISS National Lab-sponsored biomedical research, physical sciences projects, technology demonstrations, and NSF-funded science...

Caris Life Sciences to Showcase Research Highlighting the Value of Precision Oncology Collaboration at the American Association for Cancer Research Annual Meeting 2025

Caris Life Sciences to present 14 abstracts, inclusive of 2 oral presentations and 12 posters IRVING, Texas, April 17, 2025...

error: Content is protected !!